Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Merck & Co
(NY:
MRK
)
80.93
-1.46 (-1.77%)
Official Closing Price
Updated: 5:00 PM EDT, Jul 3, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Merck & Co
< Previous
1
2
3
4
5
6
7
8
9
...
87
88
Next >
Elizabeth Warren, Jan Schakowsky Reportedly Seek Answers From Pfizer, Amgen, And Others On Low Federal Tax Bills
June 17, 2025
The Democratic lawmakers alleged that pharmaceutical companies avoided paying U.S. tax bills by shifting their profits to offshore subsidiaries in jurisdictions with significantly lower tax rates, such...
Via
Stocktwits
Topics
Government
These Were the 2 Worst-Performing Stocks in the Dow Jones Industrial Average in May 2025
June 14, 2025
The Dow Jones index could have fared better in May if not for these two stocks.
Via
The Motley Fool
Topics
Government
Intellectual Property
Lawsuit
Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery
June 13, 2025
Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE-689 trial.
Via
Benzinga
Merck Gets FDA Approval For Keytruda To Treat A Broader Population Of Head And Neck Cancer Patients: Retail Stays Bullish
June 13, 2025
In the U.S., it is estimated there will be approximately 72,680 new cases of head and neck cancer diagnosed and more than 16,680 deaths from the disease in 2025, Merck said.
Via
Stocktwits
Topics
Death
Price Over Earnings Overview: Merck & Co
June 09, 2025
Via
Benzinga
Unpacking the Latest Options Trading Trends in Merck & Co
June 04, 2025
Via
Benzinga
How Do Investors Really Feel About Merck & Co?
May 30, 2025
Via
Benzinga
RFK Jr. Appointee To CDC Advisory Committee Was A Paid Expert In Merck's Gardasil Lawsuit
June 12, 2025
Martin Kulldorff, appointed by RFK Jr. to a federal vaccine panel, previously earned $33K as an expert witness in lawsuits targeting Merck's Gardasil vaccine.
Via
Benzinga
Topics
Lawsuit
10 Health Care Stocks With Whale Alerts In Today's Session
June 12, 2025
Via
Benzinga
2 Unstoppable Stocks to Consider Buying, Even Amid Market Volatility
June 12, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Government
Unpacking the Latest Options Trading Trends in Merck & Co
June 11, 2025
Via
Benzinga
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
June 11, 2025
Via
The Motley Fool
Topics
Stocks
10 Health Care Stocks Whale Activity In Today's Session
June 10, 2025
Via
Benzinga
MERCK & CO. INC. (NYSE:MRK) - A Strong Value Pick in Pharmaceuticals
June 10, 2025
MERCK & CO. INC. (NYSE:MRK) is a value stock with strong profitability, a healthy balance sheet, and an attractive dividend. Trading below industry valuations, it may appeal to long-term investors.
Via
Chartmill
Merck's Cholesterol Lowering Drug Hits Primary Goal In Two Pivotal Trials
June 09, 2025
Merck's oral PCSK9 inhibitor enlicitide showed significant LDL-C reductions in two Phase 3 trials, with no major safety concerns reported.
Via
Benzinga
Merck Announces Positive Data From Trials For Cholesterol Drug, But Retail Reaction Is Sluggish
June 09, 2025
Dean Y. Li, president of Merck Research Laboratories, said that the company is working with urgency to make the oral therapy available to patients worldwide.
Via
Stocktwits
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
June 09, 2025
Via
Benzinga
Top S&P500 movers in Monday's pre-market session
June 09, 2025
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses.
Via
Chartmill
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
June 07, 2025
Each of the index's highest-yielding names has its own unique story right now.
Via
The Motley Fool
Topics
Economy
Stocks
Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta
June 06, 2025
Byron Allen dials out, Salesforce logs in. Here are the various deal announcements of the past week plus bankruptcy updates.
Via
Benzinga
Topics
Bankruptcy
Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug
June 05, 2025
Alvotech and Dr. Reddy's will co-develop a biosimilar to Keytruda, aiming to expand global access to cancer treatment alternatives.
Via
Benzinga
9 Health Care Stocks Whale Activity In Today's Session
June 04, 2025
Via
Benzinga
1 Value Stock to Target This Week and 2 to Question
June 04, 2025
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are...
Via
StockStory
MoonLake Immunotherapeutics Catapults On Rumored Merck Takeover
June 03, 2025
The deal is being discussed ahead of key data from MoonLake in patients with a skin disease.
Via
Investor's Business Daily
Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report
June 03, 2025
Merck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it faces revenue pressure from Keytruda's looming patent cliff.
Via
Benzinga
Topics
Intellectual Property
Merck KANDLELIT Trials Spark Hope For Hard-To-Treat Cancers
May 30, 2025
Merck shared safety and efficacy results of MK-1084; either as monotherapy or in combinations, it demonstrated a manageable safety profile.
Via
Benzinga
Summit Therapeutics, A Top 1% Biotech, Plummets On A High-Profile Failure
May 30, 2025
There's a long history of anti-PD-1 and anti-VEGF drugs working to slow progression, but not improve overall survival.
Via
Investor's Business Daily
2 Cash-Producing Stocks for Long-Term Investors and 1 to Steer Clear Of
May 30, 2025
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Via
StockStory
Merck, Daiichi Sankyo Pull FDA Application For Lung Cancer Therapy: Retail Terms It A ‘Huge Flop’
May 29, 2025
The decision is based on results from a late-stage trial in which the drug failed to prolong patients' lives, the companies stated.
Via
Stocktwits
Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45%
May 29, 2025
Keros ends PAH development of cibotercept after Phase 2 safety issues, including pericardial effusions, and plans to cut 45% of workforce amid review.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
87
88
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.